Cargando…
Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors
Mutation in the CTNNB1 gene, leading to a deregulation of the WTN/β-catenin pathway, is a common feature of desmoid tumors (DTs). Many β-catenin inhibitors have recently been tested in clinical studies; however, BC2059 (also referred as Tegavivint), a selective inhibitor of nuclear β-catenin that wo...
Autores principales: | Braggio, Danielle Almeida, Costas C. de Faria, Fernanda, Koller, David, Jin, Feng, Zewdu, Abeba, Lopez, Gonzalo, Batte, Kara, Casadei, Lucia, Welliver, Meng, Horrigan, Stephen K., Han, Ruolan, Larson, Jeffrey L., Strohecker, Anne M., Pollock, Raphael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565452/ https://www.ncbi.nlm.nih.gov/pubmed/36240209 http://dx.doi.org/10.1371/journal.pone.0276047 |
Ejemplares similares
-
β-catenin S45F mutation results in apoptotic resistance
por: Braggio, Danielle, et al.
Publicado: (2020) -
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
por: Lopez, Gonzalo, et al.
Publicado: (2017) -
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
por: Fiskus, Warren, et al.
Publicado: (2014) -
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022) -
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST)
por: Lopez, Gonzalo, et al.
Publicado: (2015)